In 2021, breast cancer became the most common cancer globally, accounting for 12% of all new annual cancer cases.
In the US, it’s the most commonly diagnosed cancer among women and it’s estimated it will account for approximately 30% of new diagnoses this year.
And yet, despite the universality of the disease, current screening, and diagnostic systems leave much to be desired as far as improving health outcomes goes.
Izotropic Corporation (CSE: IZO) is an undervalued small-cap health tech company that is developing & commercializing the future of breast imaging!
The Enemy ▶ Universal
The Problem ▶ Limitations of current systems
The Solution ▶ IzoView Breast CT System
Bottom Line ▶ Future of breast imaging
Approximately 1 in 8 women will be diagnosed with breast cancer in their lifetime, and 1 in 39 will die as a result of the disease.
The disease is not without opposition: in the US alone there are over 3.8 million women who have been breast cancer survivors.
Still, there are around 290k new cases every year and it’s estimated that deaths from breast cancers will total over 43k in 2022.
This is why there have been over 41 million breast scans in the US since 2019 and why 1.4 million breast biopsies are performed every year.
But these current systems have their limitations—both economically and in overall effectiveness.
Screening mammography misses 1 out of 5 cancers and the cost of follow-up diagnostic imaging and procedures after screening totals $8B per year.
Currently, 71% of breast biopsies are negative which results in a cumulative cost of $2.2B annually.
So what do these millions of annual breast scans look like now?
There are several drawbacks to current systems that result in a long, laborious process that is unpleasant for patients and provides limited insights for professionals.
This directly affects outcomes.
Current 2D imaging modalities (mammography and tomosynthesis) require operation by significantly skilled technicians and necessitate the manipulation of breasts for multiple imaging views.
Complaints of pain and discomfort from continual breast compression and handling account for 46% of patient non-compliance.
It would be one thing if the process was painful and quick, but current systems can take 20-45 minutes technicians must capture up to 12 individuals views, each of which requires up to 20 seconds of compression per view.
Even after this long imaging workup, image distortion can pose a serious problem.
Machines can misrepresent anatomical structures because of breast compression and they make no differentiation between macro or microcalcifications (breast cancer indicators), nor do they use contrast for tumor visualization.
The problem is exacerbated for 40% of women who have dense breast tissue.
The low sensitivity (44%) provided by mammography decreases the ability to accurately detect by causing dense tissue to show up as white, which is the same color as suspicious lesions and tumors.
This can be like trying to find a golf ball in a snowstorm.
Even the latest improvement, tomosynthesis, with 2.5D imaging (vs. 2D), suffers from increased acquisition time and motion blur issues as a result of breast compression.
Izotropic Corporation is the only company in the world focused on the development and commercialization of breast cancer CT imaging (for the most accurate detection and diagnosis over current systems) that is available to ordinary investors.
Its IzoView Breast CT System offers a whole new experience for patients, radiologists, and providers by leveraging innovative (proprietary) technology.
It produces both high-resolution and low-noise images while maintaining low radiation levels.
With this new technology, a single 10-second scan can yield a data set in under 30 seconds that includes ~500 image views which are spliced together utilizing machine learning algorithms to enable true 3D imaging.
This is all done with no breast compression. The breasts’ natural orientation is preserved and patient pain and discomfort are eliminated with a comfortable, face-down position which allows for excellent visualization contrast.
That also means technician manipulation is not necessary as patients place their own breasts in the imaging cup. This may help to eliminate that 46% non-compliance we mentioned previously.
The resulting 360-degree images are ideal for patients with dense breast tissue, which as we noted is ~44% of women.
It is also anticipated that IzoView may provide more accurate margin analysis (viewing degrees of a tumor), lesion characterization (determining the qualities of an abnormality), and higher spatial resolution (imaging ability to differentiate between internal breast structures).
There is demand from all stakeholders—patients, professionals, insurance payors—for this technology and Izotropic has gained market acceptance with customers asking for IzoView today.
And for good reason, it benefits EVERYONE:
Patients 👉 enjoy a much quicker, more comfortable, and less intrusive experience which could lead to wider adoption
Doctors 👉 get higher quality images with true 3D visualization capabilities and the use of contrast expands use cases
Hospitals & clinics 👉 can get patients in and out quickly (high throughput) and attract more thanks to a significantly shorter workflow
Insurance payors 👉 could reduce costs by reducing the number of false positives leading to unnecessary biopsies (in the billions of dollars)
Discussions with these payors have already been initiated by Izotropic and are ongoing
The breast imaging market is growing quickly, expected to rise from $3.7B to $5.4B by 2025.
The technology around IzoView has been under development for over 20 years and Izotropic has exclusive global licensing rights to Breast CT through an agreement with the University of California, Davis.
In that time over $20M in R&D for breast CT evolution has been spent via government grants.
And, as we highlighted above, for everyday investors, this is the only opportunity to invest in a company working on this revolutionary imaging technology, for which a strong demand already exists.
There are future indications for use planned across multiple workstreams including screening, biopsy, treatment, monitoring, and treatment delivery.
This is to say: there are more plans than just diagnostics.
With near-term catalysts and long-term plans to offer multiple solutions for breast care, Izotropic represents the future of breast imaging and IzoView will soon become an indispensable tool for improving the outcomes of breast cancer.
The information contained on this website has been prepared by the paid advertiser Izotropic Corporation. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser. Izotropic Corporation has paid $95,000 to have this content (in addition to other content on other social media sites) created and published. GetVersed is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.
The information contained on this website has been prepared by the paid advertiser. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser.
Grit Capital Corporation is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.
THE INFORMATION CONTAINED ON THIS WEBSITE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF ANY COMPANY MAY TRADE AT ANY TIME. THE INFORMATION AND OPINIONS PROVIDED HEREIN SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND DECISIONS REGARDING THE PROSPECTS OF ANY COMPANY DISCUSSED HEREIN BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED HEREIN. INVESTORS SHOULD OBTAIN INDIVIDUAL FINANCIAL ADVICE BASED ON THEIR OWN CIRCUMSTANCES BEFORE MAKING AN INVESTMENT DECISION.
No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned.
Any projections, market outlooks or estimates herein are forward looking statements and are inherently unreliable. They are based upon certain assumptions and should not be construed to be indicative of the actual events that will occur. Other events that were not taken into account may occur and may significantly affect the returns or performance of the securities discussed herein. The information provided herein is based on matters as they exist as of the date of preparation and not as of any future date, and the publisher undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional material.
The publisher, its affiliates, and clients of the a publisher or its affiliates may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities). To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.
Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein.